3,400-year-old Egyptian town with links to King Tutankhamun unearthed near Alexandria
A French team of archaeologists have made a remarkable discovery - the ruins of a 3,400-year-old Egyptian town near the modern-day city of Alexandria, that was possibly built by the legendary King Tutankhamun's father, Akhenaten.
Detailed in a new study published in
Antiquity
, the mud-brick ruins are believed to date back to Egypt's 18th Dynasty (circa 1550–1292 BCE), a period known for its wealth, power, and dramatic shifts in religious ideology.
The site, known as Kom el-Nugus, lies 27 miles west of Alexandria, perched on a rocky ledge between the Mediterranean Sea and Lake Mariout. Although excavations began in 2013, it was long assumed that the area had only been settled during the Hellenistic period, when the Greeks arrived around 332 BCE.
'The discovery of New Kingdom remains at the site was a great surprise,' lead archaeologist Sylvain Dhennin of the University of Lyon and the French National Centre for Scientific Research told the
New Scientist
. 'This discovery completely revises the history of Egypt's western frontier in the New Kingdom.'
The ancient settlement likely dates back to Egypt's 18th Dynasty (around 1550–1292 BCE).
Credit: Cambridge University Press
A stone block featuring Ra-Horakhty, the god of the rising sun, from the temple of Ramesses II.
Credit: Cambridge Core
Among the most noteworthy finds found during the excavation were amphora jar fragments stamped with the name Merytaton, who was believed to the eldest daughter of revolutionary pharaoh Akhenaten and his queen, Nefertiti - and thus making her the sister or half-sister of Tutankhamun. The markings indicate the settlement could have been a wine production facility that may have been dedicated to her, suggesting that royal branding and product endorsements existed in ancient Egypt.
"The presence of this stamp probably indicates the production of wine belonging to a royal estate" study author Sylvain Dhennin, an archaeologist with the French National Center for Scientific Research (CNRS), told
Live Science
. "The vineyards on the margins of Egypt were probably protected by the military and formed part of a pioneering front to occupy this region towards the desert."
Other discoveries include fragments of a stele bearing the cartouches of Pharaoh Seti II (r. 1203–1197 BCE), and architectural remnants linked to a temple honouring
Ramesses II
- a ruler often speculated to be the pharaoh of the biblical Exodus.
While the full scale of the settlement remains unknown, the presence of a meticulously designed street, cleverly sloped to drain water and protect buildings from erosion, points to a town of significant size and sophistication.
Related
Archaeologists unearth 3,200-year-old tomb linked to ancient Egypt's military elite
The Bashiri mystery: A 2,300-year-old Egyptian mummy that no archaeologist dares to open
Other recent ancient Egyptian discoveries
The discovery of the settlement adds to a series of major Egyptian archaeological finds this year. Just last month, archaeologists unearthed the
tomb of Pharaoh Thutmose II
- the first pharaonic burial site found since Tutankhamun's in 1922.
Discovered by a joint British-Egyptian team led by Dr Piers Litherland, the tomb was hidden away in the Western Valleys of the Theban Necropolis, near Luxor.
The exterior of Thutmose II's tomb, discovered in the Western Valleys of the Theban Necropolis, near Luxor.
Credit: Wikimedia Commons/Amel Eweida/New Kingdom Research Foundation
Mohamed Ismail Khaled, the secretary general of Egypt's Supreme Court of Antiquities, said in a statement that the discovery was 'one of the most significant archeological breakthroughs in recent years.'
Days later, the same team announced they may have located a
second tomb
belonging to Thutmose II, buried 23 metres beneath a carefully disguised mound of rubble, limestone, ash, and mud plaster. Litherland believes the tomb could contain the pharaoh's mummified remains and grave goods. 'The best candidate for what is hidden underneath this enormously expensive, in terms of effort, pile is the second tomb of Thutmose II,' he told The Observer.
And earlier this year, a French-Swiss archaeological team in Egypt made another remarkable discovery - the tomb of a
high-ranking wizard-doctor
who served the pharaohs some 4,000 years ago. Inscriptions identify the tomb's owner as Tetinebefou, a celebrated doctor during the reign of King Pepi II (circa 2305–2118 BC).
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Euronews
6 days ago
- Euronews
Light stimulation shows promise in slowing Parkinson's, scientists say
French scientists are experimenting with a new way to combat Parkinson's disease: using light to stimulate damaged nerve cells in the brain. Researchers from a biomedical research centre affiliated with Grenoble University Hospital announced their progress on Radio France, explaining that while the trial is still at a very early stage, it could lead to breakthroughs in the treatment of the neurodegenerative disease. Around 10 million people worldwide have Parkinson's, and that figure is expected to double by 2050, according to Parkinson's Europe. There is no cure, but researchers have been searching for ways to slow the disease and alleviate symptoms, which include tremours, muscle rigidity, and slowness of movement. If it is successful in larger studies, the French clinical trial could help disrupt the progression of the disease through a non-invasive technique that stimulates the functional recovery of neurons, or nerve cells. The study targets dopamine-secreting neurons, which are critically affected as Parkinson's progresses. Around half of these cells may be damaged by the time symptoms appear, while patients lose an average of 10 per cent of their dopamine receptors per year, according to Dr Stephan Chabardès, a neurosurgeon at Grenoble University Hospital. The aim of the trial is to slow down patients' neurological deterioration, Chabardès said. The technique directs light beams to neurons deep inside the brain to target mitochondria – responsible for energy production within the cell – to stimulate them and improve their function, thereby revitalising the damaged cells. Chabardès said that in order to access these deep brain regions, the researchers developed a special compact device that combines advanced expertise in electronics, photonics, and nanotechnology, enabling the system to get smaller without sacrificing performance. "It is the combination of this medical expertise in neurosurgery with expertise in micro and nanotechnologies that makes it possible to achieve these medical feats," he said. So far, the technology has been applied to seven patients with early stages of the disease, and preliminary results indicate a slowdown in the deterioration of symptoms in three of them, especially with continued stimulation. It appeared that the light stimulation helped restore some brain function in these three cases, Chabardès said. "It's very preliminary, but what we are seeing is quite promising," Chabardès said. He noted that researchers will only launch a larger clinical trial if the study finds a tangible and stable effect.
LeMonde
27-07-2025
- LeMonde
France's Gergovie plateau continues to reveal its ancient secrets
Wearing white T-shirts stamped "INRAP" (for France's National Institute for Preventive Archaeological Research) and work pants stained with earth, about 30 people bustled around the "craftsmen's quarter" site at Gergovie, near Clermont-Ferrand. Those digging, dusting and hauling away buckets of stones and sediment under the morning sun on July 17 were mostly students from universities across France, from first-year undergraduate to master's level. Every summer since 2022, around 20 of them have joined the approximately 1,000-square-meter site "to train in excavation techniques, alongside the theoretical courses they take at their university," explained Yann Deberge, an archaeologist with INRAP and head of the site. This 70-hectare plateau overlooking the valley once served as the capital of the Arverni people. The task is not easy, as they are not the first to attempt to unearth Gergovie's past. Since 1861, at least four excavation campaigns have taken place, sometimes leaving behind "invasive traces," in the words of Deberge. "That's a handicap we've tried to turn into a strength," he said. Before plunging back into the Gallic era, the archaeologists dedicated two years to studying previous excavations: They mapped them out and conducted archival research to get inside the heads of their predecessors, rediscovering their methods of working and recording results – all while carrying out their own explorations. The exposed patch of earth shown to journalists that day could be read as "a chronological fresco." From west to east, one moves back in time, from the reign of Augustus (27 BCE to 14 CE), the most recent period of human occupation, to the Gallic period (70 BCE to 50 BCE). "What is interesting about this site is that we can observe the transition from the end of the Iron Age to the Roman period," explained Marion Dacko, a research engineer at the Maison des sciences humaines, a humanities research center in nearby Clermont-Ferrand.
Euronews
22-07-2025
- Euronews
Sanofi buys UK's Vicebio for over €1bn to expand vaccine portfolio
In the race to develop next-generation respiratory virus vaccines, French pharmaceutical company Sanofi has agreed to buy Vicebio Ltd., a privately-held biotechnology company headquartered in London, UK. Sanofi said there will be an initial cash payment of $1.15bn (€980 million) for the deal, 'with potential milestone payments of up to $450 million based on development and regulatory achievements'. 'We are excited to join Sanofi', said Emmanuel Hanon, Chief Executive Officer at Vicebio, in a statement. 'Their global scale and deep expertise in vaccine development provide the ideal environment to fully realise the potential of our innovative technology." With the acquisition, Sanofi gets Vicebio's early-stage combination vaccine candidate for two respiratory viruses, the respiratory syncytial virus (RSV) and human metapneumovirus (hMPV). Respiratory infections, affecting millions globally, often appear as cold-like illnesses that could, in severe cases, lead to pneumonia. In respiratory medication, Sanofi already has several vaccines in its portfolio against flu and RSV prevention; this latest acquisition adds a non-mRNA vaccine to its pipeline. mRNA technology is relatively new for vaccines. It teaches the body how to make a protein that triggers an immune response to protect against a specific virus, instead of using a weakened or inactivated germ to trigger this reaction. With the current deal, Sanofi also gets access to Vicebio's Molecular Clamp technology, which stabilises viral proteins in their native shape, triggering a more effective immune response. This technology is expected to speed up vaccine development and simplify manufacturing and distribution. 'This acquisition furthers Sanofi's dedication to vaccine innovation with the potential to develop next-generation combination vaccines that could provide protection to older adults against multiple respiratory viruses with a single immunisation," said Jean-François Toussaint, global head of research and development vaccines at Sanofi. The transaction is expected to close by the end of 2025, and will not have a significant impact on Sanofi's financial guidance for 2025. The pharma giant's share price was down around 0.4% before 11:00 CEST in Paris.
